KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Notes Payables: 2024-2025

Historic Notes Payables for Esperion Therapeutics (ESPR) over the last 1 years, with Sep 2025 value amounting to $54.9 million.

  • Esperion Therapeutics' Notes Payables was N/A to $54.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.9 million, marking a year-over-year change of. This contributed to the annual value of $54.6 million for FY2024, which is N/A change from last year.
  • As of Q3 2025, Esperion Therapeutics' Notes Payables stood at $54.9 million, which was up 0.18% from $54.8 million recorded in Q2 2025.
  • Over the past 5 years, Esperion Therapeutics' Notes Payables peaked at $54.9 million during Q3 2025, and registered a low of $54.6 million during Q4 2024.
  • Over the past 2 years, Esperion Therapeutics' median Notes Payables value was $54.7 million (recorded in 2025), while the average stood at $54.7 million.